A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.
Researchers conduct a retrospective cohort study of histologically diagnosed gastrointestinal stromal tumors in the Surveillance, Epidemiology, and End Results (SEER) database.
Use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time and patients treated with the therapy have improved survival over surgery alone, according to study data.
Adjuvant imatinib impacts short-term free from relapse in patients with localized, surgically resected, high/intermediate-risk gastrointestinal stromal tumors (GIST), according to interim results of an intergroup trial.
Regorafenib approved for inoperable or metastatic gastrointestinal stromal tumors.
Regorafenib, a new, targeted, oral drug, demonstrated the ability to control metastatic GIST, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.
What is the role of sunitinib malate in the treatment of sarcomas?
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|